China
Africa
Explore chapters and articles related to this topic
Endocrine Disorders, Contraception, and Hormone Therapy during Pregnancy
Published in “Bert” Bertis Britt Little, Drugs and Pregnancy, 2022
Quinagolide is a non-ergot-derived selective dopamine D2 receptor agonist. It is used to treat elevated prolactin levels (hyperprolactinemia) associated with gonadal dysfunction, including reduced libido, infertility, and osteoporosis.
Prediction and Management of Ovarian Hyperstimulation Syndrome
Published in Botros Rizk, A. Mostafa Borahay, Abdel Maguid Ramzy, Clinical Diagnosis and Management of Gynecologic Emergencies, 2020
Mohamed A. Youssef, Abdel Maguid Ramzy, Botros Rizk
Tang et al. included 16 RCTs involving 2091 high-risk women [74]. They evaluated three types of dopamine agonists: cabergoline, quinagolide, and bromocriptine. When compared with placebo or no intervention, dopamine agonists seemed effective in the prevention of moderate or severe OHSS (OR, 0.27; 95% CI, 0.19–0.39). This suggests that if 29% of women undergoing ART experience moderate or severe OHSS, the use of dopamine agonists will lower this to 7% to 14% of women. There was no evidence of a difference in live birth rate, clinical pregnancy rate, multiple pregnancy rate, or miscarriage rate. However, taking dopamine agonists (especially quinagolide) may increase the incidence of adverse events such as gastrointestinal adverse effects (OR, 4.54; 95% CI, 1.49–13.84).
Endocrine and Neuroendocrine Tumors
Published in Pat Price, Karol Sikora, Treatment of Cancer, 2020
Natasha Shrikrishnapalasuriyar, P.N. Plowman, Márta Korbonits, Ashley B. Grossman
Treatment involves cabergoline, starting with 0.25 mg once a week and increasing over 2–3 weeks to 0.5 mg once or twice a week. Resistance due to intolerable side-effects may occasionally be responsive to an alternative dopamine agonist such as bromocriptine or quinagolide, but this is a rare occurrence. Most data on safety in inducing conception have been obtained with bromocriptine, with more than 20 years’ evidence of a lack of teratogenicity or problems in pregnancy. To date, cabergoline and quinagolide appear to be equally safe, but the relative long-term experience is more limited. However, many would not switch from cabergoline to bromocriptine for the induction of conception.
State of the art, new treatment strategies, and emerging drugs for non-hormonal treatment of endometriosis: a systematic review of randomized control trials
Published in Gynecological Endocrinology, 2022
Mislav Mikuš, Salvatore Giovanni Vitale, Mario Ćorić, Vendy Zajec, Michał Ciebiera, Jose Carugno, Maurizio Nicola D’alterio, Mislav Herman, Tomislav Puževski, Stefano Angioni
Concerns about an increased incidence of valvular heart failure associated with long-term use of ergot-derived dopamine agonists led to the investigation of non ergot-derived DR2 agonists, such as quinagolide, as a potential substitute. Studies in experimental mice models of endometriosis showed that quinagolide and cabergoline were equally effective. Quinagolide is a potent and highly selective D2 agonist with much lower potency for the serotonin receptors 5-HT1A and 5-HT2A and a similar safety profile of other dopamine agonists. In addition, it has no embryotoxic or teratogenic effects and no adverse effects on implantation, pregnancy, or live birth rate. In 2020, the results of the Phase 1 clinical program conducted in Belgium to evaluate quinagolide vaginal ring for the treatment of endometriosis were published. The studies aimed to describe the pharmacokinetics and safety of quinagolide, as well as changes in reproductive hormone levels, menstrual cyclicity, and endometrial histology. Three first-phase clinical RCTs involving 134 healthy female subjects demonstrated higher bioavailability of intravaginal than oral quinagolide administration, adequate plasma concentrations of vaginally administered quinagolide throughout a menstrual cycle lasting up to 35 days, and optimal tolerability of quinagolide vaginal rings without changes in reproductive hormone levels, menstrual cyclicity, or endometrial histology [29]. Two ongoing randomized clinical trials are evaluating the effect of quinagolide vaginal ring on reducing endometriotic lesions, particularly deep infiltrating endometriosis and endometriomas, and also evaluating the efficacy of a quinagolide vaginal ring in reducing endometriosis-related pain (ClinicalTrials.gov identifier: NCT03749109, NCT03692403).
Hyperprolactinaemia in male infertility: Clinical case scenarios
Published in Arab Journal of Urology, 2018
Zeinab Dabbous, Stephen L Atkin
Quinagolide is a non-ergot derived DA agonist that has DA D2 receptor selectivity. As a specific inhibitor of prolactin secretion, quinagolide offers a favourable tolerability profile and a prolonged duration of action. An initial dose is titrated from 0.025 to 0.075 mg/day over a 7-day period. The most common side-effects include: loss of appetite, nausea, and headache [40].